Why it may matterVerify against the original reporting
Strong top-line growth, raised guidance, and a transformative acquisition expand NBIX's revenue base and optionality. Historically, EPS-beat and guidance upgrades coupled with accretive M&A tend to trigger multiple expansion for biotech peers, especially when pipeline milestones loom in 2027. However, VYKAT XR’s integration and higher R&D/S&A spend introduce near-term profitability headwinds, which may temper upside if milestones slip.
AI summary
What happened, with direct paths to the underlying reporting
Neurocrine Biosciences posted a 39% YoY Q2 revenue lift to $959M, with pro forma revenue at $998M after closing the Soleno Therapeutics acquisition. INGREZZA sales reached $716M, up 15% YoY, while CRENESSITY and VYKAT XR contributed $184M and $54M respectively (the latter from the May closing). The company raised full-year INGREZZA guidance to $2.825–$2.875B, and intensified pipeline activity with upcoming Phase 3 readouts in osavampator and direclidine for 2027. The Soleno deal provides added liquidity via a $1B revolver and broadens Neurocrine’s rare-disease portfolio, signaling a longer-term growth runway.
Total revenues Q2 2026: $959M, up 39% YoY; pro forma $998M with Soleno.
INGREZZA full-year guidance raised to $2.825B–$2.875B.
Soleno acquisition closed May 2026; NBIX adds VYKAT XR and a $1B revolver.
2027 catalysts include Phase 3 readouts for osavampator (MDD) and direclidine (schizophrenia).
How to read this signal
Transparent limits for an AI-generated research aid
StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.
Related signals
More source-backed signals connected by company or event
